Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice

Pharmaceutical Research

Volumn 27, Issue 3, 2010, Pages 421-430

  Hureaux, José ^a,b   Lagarce, Frédéric ^a,b   Gagnadoux, Frédéric ^a,b   Rousselet, Marie Christine ^a   Moal, Valérie ^a   Urban, Thierry ^a,b   Benoit, Jean Pierre ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

Biocompatibiliy; Controlled drug release; Drug delivery; In vivo test; Nanoparticle

Indexed keywords

LIPID NANOCAPSULE; NANOCAPSULE; NANOCARRIER; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LD 50; LUNG CARCINOMA; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; FEMALE; HUMANS; LIPIDS; MALE; MICE; MICE, NUDE; NANOCAPSULES; PACLITAXEL;

EID: 77949274490     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-0024-y     Document Type: Article

References (52)

1. EK Rowinsky RC Donehower 1995 Paclitaxel (taxol) N Engl J Med 332 1004 14 10.1056/NEJM199504133321507 7885406 1:STN:280:DyaK2M7ptFKisg%3D%3D
2. N Klauber S Parangi E Flynn E Hamel RJ D'Amato 1997 Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol Cancer Res 57 81 6 8988045 1:CAS:528: DyaK2sXjvFOmtw%3D%3D
3. ME Stearns M Wang 1992 Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases Cancer Res 52 3776 81 1352184 1:CAS:528:DyaK38XkvVejtL8%3D
4. D Dyeand J Watkins 1980 Suspected anaphylactic reaction to Cremophor EL Br Med J 280 1353
5. RB Weiss RC Donehower PH Wiernik T Ohnuma RJ Gralla DL Trump JR Baker Jr DA Van Echo DD Von Hoff B Leyland-Jones 1990 Hypersensitivity reactions from taxol J Clin Oncol 8 1263 8 1972736 1:STN:280:DyaK3c3ptlyitw%3D%3D
6. L van Zuylen MO Karlsson J Verweij E Brouwer P de Bruijn K Nooter G Stoter A Sparreboom 2001 Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles Cancer Chemother Pharmacol 47 309 18 10.1007/ s002800000215 11345647 1:CAS:528:DC%2BD3MXjt1Chsbo%3D (Pubitemid 32640770)
7. AG Bagnarello LA Lewis MC McHenry AJ Weinstein HK Naito AJ McCullough RJ Lederman TL Gavan 1977 Unusual serum lipoprotein abnormality induced by the vehicle of miconazole N Engl J Med 296 497 9 834227 1:STN:280: DyaE2s7gtVaitQ%3D%3D
8. M Kongshaug LS Cheng J Moan C Rimington 1991 Interaction of cremophor EL with human plasma Int J Biochem 23 473 8 10.1016/0020-711X(91)90176-N 2015955 1:CAS:528:DyaK3MXht1yqtro%3D
9. K Woodburnand D Kessel 1994 The alteration of plasma lipoproteins by cremophor EL J Photochem Photobiol B 22 197 201 10.1016/1011-1344(93)06968-9 (Pubitemid 24082918)
10. T Shimomura H Fujiwara S Ikawa J Kigawa N Terakawa 1998 Effects of taxol on blood cells Lancet 352 541 2 10.1016/S0140-6736(05)79249-7 9716061 1:STN:280:DyaK1cznvF2iug%3D%3D
11. CD Scripture WD Figg A Sparreboom 2006 Peripheral neuropathy induced by Paclitaxel: recent insights and future perspectives Curr Neuropharmacol 4 165 72 10.2174/157015906776359568 18615126 1:CAS:528:DC%2BD28XivVWmtr0%3D
12. AJ Windebank MD Blexrud PC de Groen 1994 Potential neurotoxicity of the solvent vehicle for cyclosporine J Pharmacol Exp Ther 268 1051 6 8113961 1:CAS:528:DyaK2cXitVymtLw%3D
13. GJ Lesser SA Grossman S Eller EK Rowinsky 1995 The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study Cancer Chemother Pharmacol 37 173 8 7497589 1:CAS:528:DyaK28XlvFyrsg%3D%3D
14. J Szebeni FM Muggia CR Alving 1998 Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study J Natl Cancer Inst 90 300 6 10.1093/jnci/90.4.300 9486816 1:CAS:528: DyaK1cXhsVGmtLY%3D
15. J Szebeni CR Alving S Savay Y Barenholz A Priev D Danino Y Talmon 2001 Formation of complement-activating particles in aqueous solutions of taxol: possible role in hypersensitivity reactions Int Immunopharmacol 1 721 35 10.1016/S1567-5769(01)00006-6 11357884 1:CAS:528:DC%2BD3MXit1Ohsb8%3D (Pubitemid 32206533)
16. L van Zuylen L Gianni J Verweij K Mross E Brouwer WJ Loos A Sparreboom 2000 Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients Anticancer Drugs 11 331 7 10.1097/00001813-200006000-00003 10912949 (Pubitemid 30459468)
17. VD Bowers S Locker S Ames W Jennings RJ Corry 1991 The hemodynamic effects of Cremophor-EL Transplantation 51 847 50 10.1097/00007890-199104000- 00021 2014541 1:STN:280:DyaK3M7ps1Wjuw%3D%3D
18. SC Kim DW Kim YH Shim JS Bang HS Oh S Wan Kim MH Seo 2001 In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy J Control Release 72 191 202 10.1016/S0168-3659(01)00275-9 11389998 1:CAS:528:DC%2BD3MXktVGks7s%3D (Pubitemid 32522357)
19. AL Seligson RC Terry JC Bressi JG Douglass 3rd M Sovak 2001 A new prodrug of paclitaxel: synthesis of Protaxel Anticancer Drugs 12 305 13 10.1097/00001813-200104000-00002 11335786 1:CAS:528:DC%2BD3MXktVSksrg%3D (Pubitemid 32453435)
20. DG Rodrigues DA Maria DC Fernandes CJ Valduga RD Couto OC Ibanez RC Maranhao 2005 Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies Cancer Chemother Pharmacol 55 565 76 10.1007/s00280-004-0930-y 15726368 1:CAS:528:DC%2BD2MXjslOmt7g%3D (Pubitemid 40674632)
21. S Khandavilliand R Panchagnula 2007 Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats J Invest Dermatol 127 154 62 10.1038/sj.jid.5700485 1:CAS:528: DC%2BD28XhtlSqurnI (Pubitemid 46005673)
22. JA Straub DE Chickering JC Lovely H Zhang B Shah WR Waud H Bernstein 2005 Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850) Pharm Res 22 347 55 10.1007/s11095-004-1871-1 15835739 1:CAS:528:DC%2BD2MXivVKhtLY%3D (Pubitemid 40558492)
23. HF Liang CT Chen SC Chen AR Kulkarni YL Chiu MC Chen HW Sung 2006 Paclitaxel-loaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer Biomaterials 27 2051 9 10.1016/j.biomaterials.2005.10.027 16307794 1:CAS:528:DC%2BD2MXht12isb7P (Pubitemid 41759499)
24. T Musumeci L Vicari CA Ventura M Gulisano R Pignatello G Puglisi 2006 Lyoprotected nanosphere formulations for paclitaxel controlled delivery J Nanosci Nanotechnol 6 3118 25 10.1166/jnn.2006.452 17048526 1:CAS:528: DC%2BD28XhtVKnsrzE (Pubitemid 44579990)
25. A Sharmaand RM Straubinger 1994 Novel taxol formulations: preparation and characterization of taxol-containing liposomes Pharm Res 11 889 96 10.1023/A:1018994111594 (Pubitemid 24210627)
26. TE Stinchcombe 2007 Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel Nanomed 2 415 23 10.2217/17435889.2. 4.415 1:CAS:528:DC%2BD2sXpsVaqu7w%3D (Pubitemid 47365124)
27. WJ Gradishar S Tjulandin N Davidson H Shaw N Desai P Bhar M Hawkins J O'Shaughnessy 2005 Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 7794 803 10.1200/JCO.2005.04.937 16172456 1:CAS:528:DC%2BD2MXht1Cqs7nK (Pubitemid 46657376)
28. NA Rizvi GJ Riely CG Azzoli VA Miller KK Ng J Fiore G Chia M Brower R Heelan MJ Hawkins MG Kris 2008 Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer J Clin Oncol 26 639 43 10.1200/JCO.2007.10.8605 18235124 1:CAS:528:DC%2BD1cXis1alsb4%3D (Pubitemid 351264360)
29. MG Teneriello PC Tseng M Crozier C Encarnacion K Hancock MJ Messing KA Boehm A Williams L Asmar 2009 Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer J Clin Oncol 27 1426 31 10.1200/JCO.2008.18.9548 19224848 1:CAS:528:DC%2BD1MXksF2hs74%3D
30. Abi 007 2004 Drugs R D 5 155 9 10.2165/00126839-200405030-00003 (Pubitemid 38786421)
31. P. N. EMEA/H/C/778. Assement report for Abraxane, European Medicines Agency Evaluation of Medicines for Human Use, Doc.Ref.:EMEA/47053/2008.
32. B Heurtault P Saulnier B Pech JE Proust JP Benoit 2002 A novel phase inversion-based process for the preparation of lipid nanocarriers Pharm Res 19 875 80 10.1023/A:1016121319668 12134960 1:CAS:528:DC%2BD38XltVSgtrs%3D (Pubitemid 34692585)
33. A Vonarbourg C Passirani P Saulnier P Simard JC Leroux JP Benoit 2006 Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake J Biomed Mater Res A 78 620 8 16779767 1:STN:280:DC%2BD28rgslSmtQ%3D%3D
34. A Lamprecht Y Bouligand JP Benoit 2002 New lipid nanocapsules exhibit sustained release properties for amiodarone J Control Release 84 59 68 10.1016/S0168-3659(02)00258-4 12399168 1:CAS:528:DC%2BD38XnvFOnsrY%3D (Pubitemid 35223414)
35. A Lamprecht JL Saumet J Roux JP Benoit 2004 Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment Int J Pharm 278 407 14 10.1016/j.ijpharm.2004.03.018 15196644 1:CAS:528:DC%2BD2cXkslKlsrk%3D (Pubitemid 38759512)
36. A Malzert-Freon S Vrignaud P Saulnier V Lisowski JP Benoit S Rault 2006 Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent Int J Pharm 320 157 64 10.1016/j.ijpharm.2006.04.007 16723200 1:CAS:528:DC%2BD28XnsFCqtb8%3D (Pubitemid 44128708)
37. A Lamprechtand JP Benoit 2006 Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition J Control Release 112 208 13 10.1016/j.jconrel.2006.02.014 1:CAS:528:DC%2BD28XktVWnsLw%3D
38. E Allard C Passirani E Garcion P Pigeon A Vessières G Jaouen J Benoit 2008 Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas J Control Release 130 146 53 10.1016/j.jconrel.2008.05.027 18582507 1:CAS:528:DC%2BD1cXhtVais7rO
39. MN Khalid P Simard D Hoarau A Dragomir JC Leroux 2006 Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors Pharm Res 23 752 8 10.1007/s11095-006-9662-5 16550475 1:CAS:528:DC%2BD28XktFWjsL8%3D
40. E Garcion A Lamprecht B Heurtault A Paillard A Aubert-Pouessel B Denizot P Menei JP Benoit 2006 A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats Mol Cancer Ther 5 1710 22 10.1158/1535-7163.MCT-06-0289 16891457 1:CAS:528:DC%2BD28XnslWksLo%3D (Pubitemid 44323239)
41. S Peltier JM Oger F Lagarce W Couet JP Benoit 2006 Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules Pharm Res 23 1243 50 10.1007/s11095-006-0022-2 16715372 1:CAS:528:DC%2BD28XmtFCnsLw%3D (Pubitemid 43946146)
42. J Hureaux F Lagarce F Gagnadoux L Vecellio A Clavreul E Roger M Kempf JL Racineux P Diot JP Benoit T Urban 2009 Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel Eur J Pharm Biopharm 73 239 46 10.1016/j.ejpb.2009.06.013 19560538 1:CAS:528:DC%2BD1MXhtFyhtLnF
43. J Hureaux F Lagarce F Gagnadoux A Clavreul J-P Benoit T Urban 2009 The adaptation of lipid nanocapsule formulations for blood administration in animals Int J Pharm 379 266 69 10.1016/j.ijpharm.2009.05.033 19467305 1:CAS:528:DC%2BD1MXhtVKjsrzE
44. S Irwin 1968 Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse Psychopharmacologia 13 222 57 10.1007/BF00401402 5679627 1:STN:280:DyaF1M%2FgtlCiuw%3D%3D
45. S. Roux, E. Sable, and D. R. Porsolt. Primary Observation (Irwin) Test in Rodents for Assessing Acute Toxicity of a Test Agent and its Effects on Behavior and Physiologica Function. Current Protocols in Pharmacology. 2004;10.10.1-10.10.23.
46. F Lacoeuille E Garcion JP Benoit A Lamprecht 2007 Lipid nanocapsules for intracellular drug delivery of anticancer drugs J Nanosci Nanotechnol 7 4612 7 18283853 1:CAS:528:DC%2BD1cXhtFegu70%3D
47. G Oberdorster A Maynard K Donaldson V Castranova J Fitzpatrick K Ausman J Carter B Karn W Kreyling D Lai S Olin N Monteiro-Riviere D Warheit H Yang 2005 Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy Part Fibre Toxicol 2 8 10.1186/1743-8977-2-8 16209704 1:CAS:528:DC%2BD2MXhtF2ltb3O (Pubitemid 44848692)
48. EJ Freireich EA Gehan DP Rall LH Schmidt HE Skipper 1966 Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man Cancer Chemother Rep 50 219 44 4957125 1:CAS:528:DyaF28Xkt1Cisr0%3D
49. S Ballot N Noiret F Hindre B Denizot E Garin H Rajerison JP Benoit 2006 99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution Eur J Nucl Med Mol Imaging 33 602 7 10.1007/s00259-005-0007-0 16450136 1:CAS:528:DC%2BD28XktFSqsL4%3D
50. SM Moghimi AC Hunter JC Murray 2005 Nanomedicine: current status and future prospects Faseb J 19 311 30 10.1096/fj.04-2747rev 15746175 1:CAS:528:DC%2BD2MXit1ygsLw%3D (Pubitemid 40316520)
51. A Cahouet B Denizot F Hindre C Passirani B Heurtault M Moreau J Le Jeune J Benoit 2002 Biodistribution of dual radiolabeled lipidic nanocapsules in the rat using scintigraphy and gamma counting Int J Pharm 242 367 71 10.1016/S0378-5173(02)00218-1 12176281 1:CAS:528:DC%2BD38Xmt1yntr4%3D (Pubitemid 34899490)
52. A Sharma E Mayhew L Bolcsak C Cavanaugh P Harmon A Janoff RJ Bernacki 1997 Activity of paclitaxel liposome formulations against human ovarian tumor xenografts Int J Cancer 71 103 7 10.1002/(SICI)1097-0215(19970328)71:1<103:: AID-IJC17>3.0.CO;2-J 9096672 1:CAS:528:DyaK2sXis1Kisrw%3D (Pubitemid 27158416)